



The Trinidad and Tobago Cancer Society
&
The Trinidad and Tobago Medical Association
invites ALL Medical Doctors to a CME Meeting

Theme: PROSTATE CANCER
**“Lack of Evidence-Based Medicine:
Understanding and Implementing PSA
Guidelines into Practice”**

Dr. Kevin M. Slawin, M.D.

**President & Chief Medical Officer, Bellicum Pharmaceuticals,
Director, Vanguard Urologic Institute and the Texas Prostate Center
Adjunct Professor, Center for Clinical and Translational Sciences, The University
of Texas Health Science Center - Houston
Clinical Professor of Urology, Baylor College of Medicine
Director of Urology, Memorial Hermann - Texas Medical Center**

Thursday June 6th, 2013 @ 7pm (Promptly)
The Courtyard Marriott Hotel, Invaders Bay, Port-of-Spain
Please register by e-mailing medassoc@tntmedical.com

PROUDLY SPONSORED BY: *Smith Robertson & Co. Ltd.*



Trinidad and Tobago Medical Association
 #1, Sixth Avenue, Xavier Street Extension,
 Orchard Gardens, Chaguanas
 Email: medassoc@tntmedical.com
 Telephone: 671-7378/ Tel/fax: 671-5160



Registration Form

Name of meeting: TTCS Prostate Cancer
 Date: Thursday June 6th, 2013
 Location: Courtyard Marriott, Port-of-Spain
 Time: 7pm

Please fill out the form **LEGIBLY: in block letters only**.

Title (Dr,Mr,Ms)		First Name		Surname	
Salutation	1.MD	6. MSc,PhD		11. Diploma	
	2.MBBS	7. MB, BCH, DCH, MRCPCH		12. MSc, MD	
	3.BHD	8. MB Bch, MSC, DCH		13. RN	
	4.MD, BHD	9. MBBCH, MSc		14. PhD	
	5. MSc	10. Diploma, MSc			
Kindly indicate your salutation- # ____ OTHER -					
Email					
Contact Number	1) Mobile-	2) Home-	3) Work-		
Home Address					
Hospital/ Organization					
Work address					
Certificate collection	Kindly indicate your preferred method of certificate collection: (TTPOST to Home/Work address; Will collect at TTMA office; other)				
Specialty			Department		

Thank you!

Kevin M. Slawin, M.D.

President & Chief Medical Officer, Bellicum Pharmaceuticals, Inc.
Director, Vanguard Urologic Institute and the Texas Prostate Center
Adjunct Professor, Center for Clinical and Translational Sciences, The University of Texas Health Science Center - Houston
Clinical Professor of Urology, Baylor College of Medicine
Director of Urology, Memorial Hermann - Texas Medical Center



Kevin M. Slawin, M.D., is founder and Director of the Vanguard Urologic Institute, whose mission is to embrace new ideas and technologies in science and medicine, bringing the best of them to patients with urologic diseases; and founder and Chief Medical Officer of Bellicum Pharmaceuticals, Inc, where he is developing a novel therapeutic vaccine for patients with advanced prostate cancer.

Dr. Slawin earned his medical degree at Columbia University before training in general and reconstructive surgery at Mount Sinai Hospital, New York. He returned to Columbia-Presbyterian Medical Center to complete his urological training under Carl Olsson, M.D., and subsequently was awarded a two-year AFUD fellowship with world-renowned prostate cancer expert Peter Scardino, M.D. (then Chairman of the Scott Department of Urology, Baylor College of Medicine, currently Chairman of the Department of Surgery at Memorial Sloan Kettering), to study the development and treatment of prostate cancer. He succeeded Dr. Scardino as Director of the Baylor Prostate Center in 1994.

At Vanguard, Dr. Slawin specializes in urologic oncology, and benign and malignant diseases of the prostate. He has been a leader in the field of robotic surgery since its inception and is a founding editor of the *Journal of Robotic Surgery*. He was the first to perform robotic radical prostatectomy in the Texas Medical Center in 2001, and has since performed well over 2000 radical prostatectomies, including over 900 performed robotically, using a unique extra-peritoneal approach, recognized as technically more difficult to perform but yielding significant advantages to patient recovery.

His recent clinical research interests have focused on improving cancer and quality of life outcomes for patients with prostate cancer, backed by a long history of collaborative basic research efforts that have already led to successful FDA approved products. For example, he is a co-discoverer and inventor of the novel molecular PSA forms “BPSA”, associated with benign enlargement of the prostate, and “[2]proPSA”, associated with prostate cancer, both licensed to Beckman Coulter, Inc. Dr. Slawin led Vanguard’s participation in pivotal trials of a [2]proPSA blood test, in support of an application for FDA approval for use in men to improve the accuracy of prostate cancer screening. The test recently received regulatory approval in Europe and is marketed by Beckman Coulter as the “prostate health index (phi)”.

His desire to translate cutting edge technologies to the benefit of patients coupled with his entrepreneurial spirit has led Dr. Slawin to found Oncovance Technologies, Inc., a web-based disease prediction company, and Bellicum Pharmaceuticals, Inc., whose cancer vaccine BPX-101 is currently under evaluation in a Phase I/II clinical trial in men with metastatic castrate resistant prostate cancer, where it has shown preliminary evidence of clinical efficacy. BPX-101 is based on DOD- and NIH-funded scientific and preclinical work conducted by Dr Slawin in collaboration with Dr. David Spencer at Baylor College of Medicine and published in the top medical science journals *Nature Medicine* and *Cancer Research*.

Author of numerous papers on the subject of prostate cancer and BPH, Dr. Slawin is a section editor of *Urology*, a member of the Editorial Board of *Reviews in Urology*, a member of the Board of Consultants for the *Journal of Urology*, a consulting editor for the journal, *Prostate Cancer and Prostatic Diseases*, and serves as reviewer and consultant for several other scientific journals. He co-edited the “Atlas of the Prostate, Third Edition” together with Dr. Peter Scardino. He received the F. Brantley Scott, M.D., Jr. Award for Innovation and Creativity in Urology.